A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01133509 |
Recruitment Status : Unknown
Verified August 2012 by Alicia Devine, MD, Eastern Virginia Medical School.
Recruitment status was: Recruiting
First Posted : May 31, 2010
Last Update Posted : August 23, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In this pilot study, we intend to demonstrate that a great portion of women at high risk (inadequate screening, HPV 16/18 and/or cytology) are presenting to the ED, cytology/ HPV testing via ThinPrep®Pap testTM and surveillance. We intend to provide improved access to healthcare and monitoring through administration of vaccine to eligible patients and 1 year follow up for patients involved in this study.
Females meeting inclusion/exclusion criteria participating in the study (n=100) that have not had a cytology test in 2 or more years will be offered the Thin Prep® cytology test. This study will allow surveillance of disease through cytology and HPV DNA testing via collection of data using Thin Prep® cytology with reflex HPV DNA testing according to established guidelines as described below.
Provide improved access to healthcare and monitoring through administration of vaccine for eligible females as established by guidelines. Patients will receive first vaccine in the ED and will have arranged follow up for administration of the 2 month and 6 month series of the HPV vaccination. Through data collection, we intend to determine if there is a need for vaccination and determine if patients are likely to follow up..
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Genital Human Papilloma Virus Infection | Drug: Gardasil | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Model for the Implementation of the Cervical Cancer Screening and HPV Vaccination in the Emergency Department: a Pilot Study. |
Study Start Date : | September 2009 |
Estimated Primary Completion Date : | September 2012 |
Estimated Study Completion Date : | October 2012 |
Arm | Intervention/treatment |
---|---|
gardisil
gardisil
|
Drug: Gardasil
0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
Other Name: Human Papillomarvirus, HPV vaccine, Gardisil, Silgard |
- To demonstrate that a great portion of women at high risk (inadequate screening, HPV 16/18 and /or cytology)are presenting to the ED,by analysis of a constructed survey,cytology/HPV testing via ThinPrep Pap test and surveillance [ Time Frame: two years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 26 Years (Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- 3 years of beginning sexual activity or by age 21 years whichever occur first.
- resident of the City of Norfolk, Virginia
- uninsured
Exclusion Criteria:
- Pregnant women
- Women with Hysterectomy with cervical excision
- Women who received full HPV vaccine series
- Known history of cervical cancer
- Male sex
- Loop electrocautery excision procedure(LEEP)
- Cold-Knife conization

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01133509
Contact: Alicia Devine, MD | 757-388-3397 | aliciadevine@mac.com | |
Contact: LaBarbara Edlow, RN | 757-388-5224 | ldedlow@sentara.com |
United States, Virginia | |
Sentara Norfolk General Hospital | Recruiting |
Norfolk, Virginia, United States, 23507 | |
Principal Investigator: Alicia S Devine, MD, JD |
Principal Investigator: | Alicia Devine, MD | Eastern Virginia Medical School |
Publications:
Responsible Party: | Alicia Devine, MD, Principal Investigator, Eastern Virginia Medical School |
ClinicalTrials.gov Identifier: | NCT01133509 |
Other Study ID Numbers: |
33249 |
First Posted: | May 31, 2010 Key Record Dates |
Last Update Posted: | August 23, 2012 |
Last Verified: | August 2012 |
Papillomavirus Infections Uterine Cervical Neoplasms Papilloma Emergencies Disease Attributes Pathologic Processes Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases |
Uterine Diseases Virus Diseases Infections Neoplasms, Squamous Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type DNA Virus Infections Tumor Virus Infections Vaccines Immunologic Factors Physiological Effects of Drugs |